Ankylosing Spondylitis Pipeline Outlook 2025: Insights Into Therapies, Research, And Market Potential

DelveInsight's, “Ankylosing Spondylitis (Bekhterev's Disease) Pipeline Insight, 2025,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Ankylosing Spondylitis (Bekhterev's Disease) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Ankylosing Spondylitis Pipeline? Click here to explore the therapies and trials making headlines @ Ankylosing Spondylitis Pipeline Outlook Report

Key Takeaways from the Ankylosing Spondylitis Pipeline Report

• On 01 August 2025, UCB Biopharma SRL conducted a study is to demonstrate the long-term safety, tolerability and efficacy of bimekizumab in patients with active axial spondyloarthritis (axSpA, also known as radiographic axSpa (r-axSpA)) including ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (nr-axSpa).
• DelveInsight's Ankylosing Spondylitis Pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Ankylosing Spondylitis treatment.
• The leading Ankylosing Spondylitis Companies such as Jiangsu Vcare Pharmaceutical Technology, Lynk Pharmaceuticals, Suzhou Zelgen Biopharmaceuticals, UCB Biosciences, Akeso, NB Health Laboratory, Funpep, Shilpa Biologicals and others.
• Promising Ankylosing Spondylitis Therapies such as AK111, LNK01001, Secukinumab, Jaktinib, Bimekizumab, SHR-1314, and others.

Want to know which companies are leading innovation in Ankylosing Spondylitis? Dive into the full pipeline insights @ Ankylosing Spondylitis Clinical Trials Assessment

The Ankylosing Spondylitis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Ankylosing Spondylitis Pipeline Report also highlights the unmet needs with respect to the Ankylosing Spondylitis.

Ankylosing Spondylitis Overview

Ankylosing Spondylitis (Bekhterev's Disease) is a type of arthritis that causes inflammation in the joints and ligaments of the spine. It may also affect peripheral joints like the knees, ankles, and hips. Normally, the joints and ligaments in the spine help us move and bend. If you have ankylosing spondylitis, the inflammation in the joints and tissues of the spine can cause stiffness. In severe cases, this may cause the vertebrae (bones in the spine) to fuse (grow together). When the vertebrae fuse, it can lead to a rigid and inflexible spine.

Ankylosing Spondylitis (Bekhterev's Disease) Emerging Drugs

• AK111: Akeso

AK111 is a novel drug targeting IL-17A of autoimmune treatment diseases independently developed by the Company. AK111 is intended to be used for the treatment of psoriasis, ankylosing spondylitis and axial spondylitis. Through a combination of competitive blockers, namely IL-17A and IL-17RA, and blocking the biological activities of IL-17, AK111 has reached the efficacy in immune-related diseases in clinical therapies. Currently, the drug is in Phase III stage of its clinical trial for the treatment of ankylosing spondylitis.

• Jaktinib: Suzhou Zelgen Biopharmaceuticals

Jaktinib hydrochloride, developed by Suzhou Zelgen Biopharmaceuticals, is a novel Janus kinase (JAK) inhibitor. It acts by targeting tyrosine protein kinases JAK1, JAK2, and JAK3, thereby inhibiting the JAK signaling pathway. This mechanism of action (moA) is crucial in treating various diseases, including myelofibrosis, graft versus host disease, rheumatoid arthritis, plaque psoriasis, idiopathic pulmonary fibrosis, autoimmune disorders, novel coronavirus pneumonia (COVID-19), and Ankylosing Spondylitis (Bekhterev's Disease). Currently, the drug is in Phase III stage of its clinical trial for the treatment of ankylosing spondylitis.

• VC005: Jiangsu Vcare Pharmatech

VC005 is a novel, highly efficient, and selective JAK1 inhibitor, as well as a second-generation inhibitor, independently developed by Jiangsu Vcare. By selectively inhibiting JAK1 kinase, decreasing the inflammatory response, and reducing the activation of immune cells, VC005 displays high potential for the treatment of inflammatory and autoimmune diseases. The in vitro kinase test results indicated that VC005 exhibited a lower inhibitory activity against JAK2 kinase compared to an approved dominant JAK inhibitor, Upadacitinib, thus it is expected to alleviate many safety concerns associated with excessive JAK2 kinase inhibition. Currently, the drug is in Phase II stage of its clinical trial for the treatment of ankylosing spondylitis.

If you're tracking ongoing Ankylosing Spondylitis Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Ankylosing Spondylitis Treatment Drugs

The Ankylosing Spondylitis Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Ankylosing Spondylitis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ankylosing Spondylitis Treatment.
• Ankylosing Spondylitis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Ankylosing Spondylitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ankylosing Spondylitis market.

Ankylosing Spondylitis Companies

Jiangsu Vcare Pharmaceutical Technology, Lynk Pharmaceuticals, Suzhou Zelgen Biopharmaceuticals, UCB Biosciences, Akeso, NB Health Laboratory, Funpep, Shilpa Biologicals and others.

Ankylosing Spondylitis (Bekhterev's Disease) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Intramuscular
• Topical

Ankylosing Spondylitis Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

From emerging drug candidates to competitive intelligence, the Ankylosing Spondylitis Pipeline Report covers it all – check it out now @ Ankylosing Spondylitis Market Drivers and Barriers, and Future Perspectives

Scope of the Ankylosing Spondylitis Pipeline Report

• Coverage- Global
• Ankylosing Spondylitis Companies- Jiangsu Vcare Pharmaceutical Technology, Lynk Pharmaceuticals, Suzhou Zelgen Biopharmaceuticals, UCB Biosciences, Akeso, NB Health Laboratory, Funpep, Shilpa Biologicals and others.
• Ankylosing Spondylitis Therapies- AK111, LNK01001, Secukinumab, Jaktinib, Bimekizumab, SHR-1314, and others.
• Ankylosing Spondylitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Ankylosing Spondylitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research – discover what's next for the Ankylosing Spondylitis Treatment landscape in this detailed analysis @ Ankylosing Spondylitis Emerging Drugs and Major Players

Table of Contents